- Strong investor demand for CVS Health's $40 billion M&A bond gave a shot of confidence to the U.S. high-grade bond market.
- It was the third largest U.S. dollar high-grade corporate deal on record.
- The CVS bond will help finance the $69 billion acquisition of health insurer Aetna.
Strong investor demand for CVS Health's U.S. $40 billion M&A bond gave a shot of confidence to the U.S. high-grade bond market Tuesday after a recent bout of volatility in the usually rock solid asset class.
Order books of more than $120 billion for the nine-tranche trade — the third largest U.S. dollar high-grade corporate deal on record, according to IFR data — brought some relief after new issues have traded wider in secondary of late.
"This is the deal of 2018," Matt Brill, senior portfolio manager at Invesco, told IFR. "The market needs this to do well."
The CVS bond, which will help finance the $69 billion acquisition of health insurer Aetna, had been hailed as a crucial test for the market that has provided some of the largest corporations with cheap financing for several consecutive years.
CVS had been eyeing other currencies as well due to the large amount of debt it needed to raise.
But hefty demand for the U.S. dollar offering helped alleviate concerns about investor demand that has tapered off in recent weeks, according to Lipper data.
The asset class, for example, last month saw its biggest weekly outflow since November 2016. Analysts have also warned about wilting demand from foreign investors as hedging costs have risen.
"The market at this juncture still has the capacity to finance large-scale transactions," said a banker not directly involved in the CVS deal.
Some investors, however, cautioned that other would-be borrowers may not find as welcome a reception.
Some, for example, gave CVS credit for the acquisition which will create one of the largest companies in the US by revenue and help cut costs. It could also help the firm resist Amazon's entry into drug distribution.
"CVS has fundamentally changed its business through this acquisition," Janelle Woodward, global co-head of income at BMO Global Asset Management, said.
Brill described the merged entity — the M&A deal is yet to close — as almost a conglomerate.
"It will have multiple sources of revenue, and will be an industry leader in multiple areas," Brill said.
To win over investors, CVS also offered a steep discount on some of the tranches that include a special mandatory redemption clause.
That clause, offered on every tranche except the 30-year, requires CVS to buy the bonds back from investors at a price of 101 if the merger fails to close by September 3 next year.
Bond buyers hailed the discount as a break-through.
Still, the huge order book is one of the largest ever recorded in the corporate bond market, according to IFR data.
Mindful of the recent choppy backdrop, Bank of America/Merrill Lynch, Barclays, Goldman Sachs, and JP Morgan — active bookrunners on the CVS trade — closed books unusually early by 10:30 a.m. New York time, and launched it just after midday.
That strategy also allowed accounts whose orders weren't filled to buy bonds in the secondary market on the same day of pricing, Brill said. The deal was trading tighter in the gray market on Tuesday afternoon after launch.
Relatively generous initial price thoughts on the trade, comprising maturities ranging from two to 30 years, certainly helped turn heads on the buyside from the get-go.
IFR calculated new issue concession of between 30 basis points (bp) to 40 bp across the deal at IPTs stage, based on where outstanding bonds from CVS were trading. The only exceptions were the two and three-year bonds, which began with NICs closer to 15bp to 25bp.
But as order books swelled, and leads pulled in spreads, NICs were closer to 10bp to 18bp on the longest tranches at launch, and 2bp to 4bp on the two shortest dated offerings, IFR calculations show.
InBev, by comparison, paid new issue concessions ranging between negative 5bp and plus 20bp on its multi-tranche offering that helped finance its acquisition of SABMiller, according to IFR calculations.
The CVS deal, rated Baa1 by Moody's and BBB by S&P, is due to price later on Tuesday.